Inventiva Sa (NASDAQ: IVA) — Perfil da empresa, notícias e dados financeiros
Inventiva is a biopharmaceutical company developing oral therapies for unmet needs in fibrosis and oncology.
Inventiva Sa
Inventiva (EPA:IVA), (NASDAQ:IVA) is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need, particularly in the realms of fibrosis, lysosomal storage disorders, and oncology. Its pipeline is led by lanifibranor, which is in Phase IIb development for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Inventiva is also advancing a second candidate, odiparcil, aimed at treating patients with mucopolysaccharidosis, a group of lysosomal storage disorders. With each project, Inventiva aims to leverage its expertise in nuclear receptor, transcription factor, and epigenetics to discover and develop novel therapeutics. The company is also listed on the Euronext Paris under the ticker (EPA:IVA), indicating its commitment to expanding its reach and enhancing shareholder value through multiple market presences.
Resumo
Operações
Produtos e/ou serviços de Inventiva Sa
- Lanifibranor, a treatment targeting non-alcoholic steatohepatitis (NASH) and other fibrotic diseases.
- Research focusing on the development of drugs leveraging the YAP-TEAD transcriptional complex for fibrotic conditions.
- Partnerships for innovative therapies in fibrosis and rare diseases.
- Odiparcil, a therapy aimed at treating mucopolysaccharidoses.
- A range of preclinical candidates addressing various fibrotic diseases.
- Technology platforms for drug discovery, including YAP-TEAD inhibitors.
equipe executiva do Inventiva Sa
- Andrew ObenshainChief Executive Officer
- Pierre BroquaCo-Founder
- Jean VolatierExecutive VP Finance & Corporate Social Responsibility
- Martine ZimmermannExecutive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs
- Jason A. CampagnaPresident of Research & Development and Chief Medical Officer
- Axel-Sven MalkomesChief Financial Officer
- Christopher BenecchiChief Operating Officer
- Susan ColesChief Legal Officer
- Pamela HerbsterChief People Officer
- Pascaline ClercExecutive Vice President of External & Corporate Affairs
Principais indicadores financeiros
Resultados divulgados pela Inventiva Sa, em EUR.
- Cap. de mercado
- 870,5 mi
- Receita (TTM)
- 2,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,5 mi | -130,9 mi | -340,2 mi | |
| 9,2 mi | -97,6 mi | -184,2 mi | |
| 17,5 mi | -102,7 mi | -110,4 mi | |
| 12,2 mi | -57,1 mi | -54,3 mi |